Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

被引：1
|
作者：
Perez
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 20期
关键词：
D O I：
10.1200/JCO.2017.74.3971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2342 / 2342
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis
    Shen, Kai
    Ma, Xuelei
    Zhu, Chenjing
    Wu, Xin
    Jia, Hongyuan
    SCIENTIFIC REPORTS, 2016, 6
  • [22] Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: An Integrated Safety Analysis
    Dieras, Veronique
    Harbeck, Nadia
    Budd, G. Thomas
    Greenson, Joel K.
    Guardino, Alice E.
    Samant, Meghna
    Chernyukhin, Nataliya
    Smitt, Melanie C.
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2750 - +
  • [23] Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (01) : 54 - 56
  • [24] Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer
    Sotelo, Miguel J.
    Angel Garcia-Saenz, Jose
    Manso, Luis
    Moreno, Fernando
    Ciruelos, Eva
    Callata, Hector R.
    Mendiola, Cesar
    Cabezas, Santiago
    Ghanem, Ismael
    Diaz-Rubio, Eduardo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (04) : 967 - 972
  • [25] Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
    Gelmon, Karen A.
    Boyle, Frances M.
    Kaufman, Bella
    Huntsman, David G.
    Manikhas, Alexey
    Di Leo, Angelo
    Martin, Miguel
    Schwartzberg, Lee S.
    Lemieux, Julie
    Aparicio, Samuel
    Shepherd, Lois E.
    Dent, Susan
    Ellard, Susan L.
    Tonkin, Katia
    Pritchard, Kathleen I.
    Whelan, Timothy J.
    Nomikos, Dora
    Nusch, Arnd
    Coleman, Robert E.
    Mukai, Hirofumi
    Tjulandin, Sergei
    Khasanov, Rustem
    Rizel, Shulamith
    Connor, Anne P.
    Santillana, Sergio L.
    Chapman, Judith-Anne W.
    Parulekar, Wendy R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (14) : 1574 - +
  • [26] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
    Baselga, Jose
    Gelmon, Karen A.
    Verma, Shailendra
    Wardley, Andrew
    Conte, PierFranco
    Miles, David
    Bianchi, Giulia
    Cortes, Javier
    McNally, Virginia A.
    Ross, Graham A.
    Fumoleau, Pierre
    Gianni, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1138 - 1144
  • [27] Ado-trastuzumab emtansine - The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
    Ganguly, Sandip
    Ghosh, Joydeep
    Biswas, Bivas
    Dabkara, Deepak
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (02) : 218 - 220
  • [28] A COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTANSINE IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE UNRESECTABLE OR METASTATIC BREAST CANCER IN PORTUGAL
    Andrade, A.
    Sousa, R.
    Silva, Almeida E.
    Macedo, B.
    Tavares, A. L.
    VALUE IN HEALTH, 2024, 27 (12) : S90 - S91
  • [29] Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA
    Swain, Sandra M.
    Im, Young-Hyuck
    Im, Seock-Ah
    Chan, Valorie
    Miles, David
    Knott, Adam
    Clark, Emma
    Ross, Graham
    Baselga, Jose
    ONCOLOGIST, 2014, 19 (07): : 693 - 701
  • [30] Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Bines, Jose
    Procter, Marion
    Restuccia, Eleonora
    Viale, Giuseppe
    Zardavas, Dimitrios
    Suter, Thomas
    Arahmani, Amal
    Van Dooren, Veerle
    Baselga, Jose
    Clark, Emma
    Eng-Wong, Jennifer
    Gelber, Richard D.
    Piccart, Martine
    Mobus, Volker
    de Azambuja, Evandro
    CLINICAL BREAST CANCER, 2020, 20 (02) : 174 - +
12345